Search for content, post, videos

Genmab achieves second milestone

genmab

Genmab has reached a USD 5 million milestone in its daratumumab collaboration with Janssen Biotech, Inc. (Janssen).  This is the second milestone payment triggered by progress in the ongoing Phase II study (“Carina” LYM2001) of daratumumab in NHL.

The study evaluates daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL).  This milestone is related to progress in the arm of the study treating patients with FL.

“The daratumumab study in NHL is now underway, and we are very pleased to have achieved milestones for progress in two of the disease areas included in the study, FL and DLBCL,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.  “We remain optimistic about the therapeutic potential of daratumumab in indications outside of multiple myeloma.”

Daratumumab has received Orphan Drug designation from the US FDA for DLBCL, MCL and FL.